Journal of Cancer Research and Therapeutics Close
 

Figure 1: The micro positron emission tomography images of tumor-bearing nude mice. No obvious decrease of SUV values of tumors in 18F-fluorodeoxyglucose (18F-FDG) imaging before (a) and after (b) 60 mmol/L gemcitabine treatments was observed, and SUV values of 18F-FDG imaging were 0.53 and 0.71, respectively. A decrease in 18F-FDG imaging before (c) and after (d) 120 mmol/L gemcitabine treatment was observed, and SUV values of 18F-FDG imaging were 0.67 and 0.55, respectively. An obvious decrease in 18F-fluorothymidine (18F-FLT) imaging before (e) and after (f) 60 mmol/L gemcitabine treatment was observed, and SUV values of 18F-FLT imaging were 1.10 and 0.38, respectively

Figure 1: The micro positron emission tomography images of tumor-bearing nude mice. No obvious decrease of SUV values of tumors in <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) imaging before (a) and after (b) 60 mmol/L gemcitabine treatments was observed, and SUV values of <sup>18</sup>F-FDG imaging were 0.53 and 0.71, respectively. A decrease in <sup>18</sup>F-FDG imaging before (c) and after (d) 120 mmol/L gemcitabine treatment was observed, and SUV values of <sup>18</sup>F-FDG imaging were 0.67 and 0.55, respectively. An obvious decrease in <sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) imaging before (e) and after (f) 60 mmol/L gemcitabine treatment was observed, and SUV values of <sup>18</sup>F-FLT imaging were 1.10 and 0.38, respectively